Amneal Pharmaceuticals, Inc. AMRX
1 trading plan running, 6 Form 144 notices for $11.0M
10-Q, 10-K and Form 144What AMRX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Aug 15, 2024 to Dec 31, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Deborah Autor a director |
Adopted 10b5-1 plan | Sep 5, 2025 | 10-Q Nov 6, 2025 | ||
What the company wroteOn September 5, 2025, Deborah Autor, a director of the Company, adopted a trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. Ms. Autor’s plan provides for the sale of 34,819 shares of Class A common stock upon the vesting of restricted stock unit awards through December 31, 2026. | |||||
| Gautam Patel a director |
Adopted 10b5-1 plan | Aug 15, 2024 | 10-Q Nov 12, 2024 | ||
What the company wroteOn August 15, 2024, Gautam Patel, a director of the Company, adopted a 10b5-1 trading plan. Mr. Patel’s plan provides for the sale of 480,000 shares of Class A common stock of the Company through June 30, 2025. | |||||
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Aug 13, 2026 | JOHN KIELY Director |
50,000 | $880K |
| Aug 12, 2026 | NIKITA SHAH Officer |
146,403 | $2.6M |
| Aug 12, 2026 | JASON DALY OFFICER |
210,000 | $3.6M |
| Aug 11, 2026 | BUCHI J KEVIN Director |
168,573 | $2.9M |
| May 11, 2026 | DEBORAH AUTOR DIRECTOR |
34,819 | $450K |
| Nov 17, 2025 | Nark Ted C Director |
50,000 | $591K |
From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/AMRX/export.csv") into a cell.